Overview

  • Product name

  • Description

    Rabbit polyclonal to MMP1
  • Host species

    Rabbit
  • Specificity

    This antibody binds to MMP1, but does not cross react with the other MMP family members (MMP2, MMP3, MMP9).
  • Tested applications

    Suitable for: IHC-P, ICC/IF, IHC-Fr, WBmore details
  • Species reactivity

    Reacts with: Horse, Dog, Human
  • Immunogen

    Synthetic peptide corresponding to MMP1. based on the hemopexin domain of the human sequence
    (Peptide available as ab41003)

Properties

Applications

Our Abpromise guarantee covers the use of ab38929 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent concentration.
ICC/IF Use at an assay dependent concentration. PubMed: 18434409
IHC-Fr Use at an assay dependent concentration.
WB 1/5000. Predicted molecular weight: 54 kDa. When used against the reduced protein this antibody identifies bands at 53 Kd and 51 Kd (the pro-form), as well as the initial active forms. Dilution optimised using Chromogenic detection.

Target

  • Function

    Cleaves collagens of types I, II, and III at one site in the helical domain. Also cleaves collagens of types VII and X. In case of HIV infection, interacts and cleaves the secreted viral Tat protein, leading to a decrease in neuronal Tat's mediated neurotoxicity.
  • Sequence similarities

    Belongs to the peptidase M10A family.
    Contains 4 hemopexin-like domains.
  • Domain

    There are two distinct domains in this protein; the catalytic N-terminal, and the C-terminal which is involved in substrate specificity and in binding TIMP (tissue inhibitor of metalloproteinases).
    The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
  • Post-translational
    modifications

    Undergoes autolytic cleavage to two major forms (22 kDa and 27 kDa). A minor form (25 kDa) is the glycosylated form of the 22 kDa form. The 27 kDa form has no activity while the 22/25 kDa form can act as activator for collagenase.
  • Cellular localization

    Secreted > extracellular space > extracellular matrix.
  • Information by UniProt
  • Database links

  • Alternative names

    • 27 kDa interstitial collagenase antibody
    • CLG antibody
    • CLGN antibody
    • collagenase, fibroblast antibody
    • collagenase, interstitial antibody
    • Fibroblast collagenase antibody
    • Interstitial collagenase antibody
    • Matrix metallopeptidase 1 (interstitial collagenase) antibody
    • Matrix metalloprotease 1 antibody
    • Matrix Metalloproteinase 1 antibody
    • Matrix metalloproteinase-1 antibody
    • MMP 1 antibody
    • MMP-1 antibody
    • MMP1 antibody
    • MMP1_HUMAN antibody
    • OTTHUMP00000045866 antibody
    see all

Images

  • All lanes : Anti-MMP1 antibody (ab38929)

    Lane 1 : Human MMP1.
    Lane 2 : Cell Media from human chondrosarcoma (no treatment).
    Lane 3 : Cell Media from human chondrosarcoma (treated with TPA).

    Predicted band size: 54 kDa
    Observed band size: 53 kDa
    why is the actual band size different from the predicted?

  • ab38929 staining MMP1 in Horse fibroblast cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with formaldehyde and blocked with 0.1% serum for 30 minutes. Samples were incubated with primary antibody (1/100) for 1 hour. An undiluted FITC-conjugated Mouse anti-rabbit IgG polyclonal was used as the secondary antibody. F-actin stained red and nuclear stained in blue with DAPI

    See Abreview

References

This product has been referenced in:

  • Zhang W  et al. Cell-free therapy based on adipose tissue stem cell-derived exosomes promotes wound healing via the PI3K/Akt signaling pathway. Exp Cell Res 370:333-342 (2018). Read more (PubMed: 29964051) »
  • Takei Y  et al. FGFRL1 deficiency reduces motility and tumorigenic potential of cells derived from oesophageal squamous cell carcinomas. Oncol Lett 16:809-814 (2018). Read more (PubMed: 29963148) »
See all 26 Publications for this product

Customer reviews and Q&As

Filter by Application

Filter by Species

Filter by Ratings

1-6 of 6 Abreviews

Application
Western blot
Sample
Human Cell lysate - whole cell (A549)
Gel Running Conditions
Non-reduced Non-Denaturing (Native)
Loading amount
60 µg
Specification
A549
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 37°C

Abcam user community

Verified customer

Submitted Apr 06 2016

Application
Western blot
Sample
Human Cell lysate - whole cell (MCF7)
Loading amount
100000 cells
Specification
MCF7
Gel Running Conditions
Reduced Denaturing
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 24°C

Abcam user community

Verified customer

Submitted May 23 2012

Application
Western blot
Sample
Horse Tissue lysate - other (Cartilage explant culture secretome)
Loading amount
50 µg
Specification
Cartilage explant culture secretome
Gel Running Conditions
Reduced Denaturing (10% gel)
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C

Dr. Ali Mobasheri

Verified customer

Submitted Jan 20 2011

Application
Immunohistochemistry (Frozen sections)
Sample
Human Tissue sections (human fetal heart)
Specification
human fetal heart
Fixative
Paraformaldehyde
Permeabilization
Yes - saponin 0.1% in PBS
Blocking step
Serum as blocking agent for 45 minute(s) · Concentration: 10% · Temperature: 37°C

Abcam user community

Verified customer

Submitted May 29 2009

Application
Immunocytochemistry/ Immunofluorescence
Sample
Horse Cell (fibroblast)
Specification
fibroblast
Fixative
Formaldehyde
Blocking step
Serum as blocking agent for 30 minute(s) · Concentration: 0.1%

Dr. Yuan ZhengQiang

Verified customer

Submitted Apr 03 2007

Application
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample
Horse Tissue sections (skin tumor)
Specification
skin tumor
Fixative
Paraformaldehyde
Antigen retrieval step
Heat mediated
Blocking step
Serum as blocking agent for 30 minute(s) · Concentration: 0.1%

Abcam user community

Verified customer

Submitted Mar 30 2007

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up